Efficacy of stellate ganglion block in treatment of electrical storm: a systematic review and meta-analysis

Pouya Motazedian,Nicholas Quinn,George A Wells,Nickolas Beauregard,Eric Lam,Marie-Eve Mathieu,William Knoll,Graeme Prosperi-Porta,Valentina Ly,Simon Parlow,Pietro Di Santo,Omar Abdel-Razek,Richard Jung,Trevor Simard,Jacob C Jentzer,Rebecca Mathew,F Daniel Ramirez,Benjamin Hibbert
DOI: https://doi.org/10.1038/s41598-024-76663-9
2024-10-21
Abstract:Electrical storm (ES) is a life-threatening condition of recurrent ventricular arrhythmias (VA) in a short period of time. Percutaneous stellate ganglion blockade (SGB) is frequently used - however the efficacy is undefined. The objective of our systematic review was to determine the efficacy of SGB in reducing VA events and mortality among patients with ES. A search of Medline, EMBASE, Scopus, CINAHL and CENTRAL was performed on February 29, 2024 to include studies with adult patients (≥ 18 years) with ES treated with SGB. Our outcomes of interest were VA burden pre- and post-SGB, and in-hospital/30-day mortality. A total of 553 ES episodes in 542 patients from 15 observational studies were included. Treated VAs pre- and post-SGB were pooled from eight studies including 383 patients and demonstrated a decrease from 3.5 (IQR 2.25-7.25) to 0 (IQR 0-0) events (p = 0.008). Complete resolution after SGB occurred in 190 of 294 patients (64.6%). Despite this, in-hospital or 30-day mortality remained high occurring in 140 of 527 patients (random effects prevalence 22%). Repeat SGB for recurrent VAs was performed in 132 of 490 patients (random effects prevalence 21%). In conclusion, observational data suggests SGB may be effective in reducing VAs in ES. Definitive studies for SGB in VA management are needed. Study protocol: PROSPERO - registration number CRD42023430031.
What problem does this paper attempt to address?